AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02062892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Patients will be stable kidney transplant patients who are receiving an immunosuppressive drug regimen based on tacrolimus and sirolimus. 24 hours after the last sirolimus dose, the patients randomized to the tacrolimus/everolimus arm of the study will be switched from sirolimus to everolimus 1:1 (same sirolimus as everolimus dose). Everolimus doses will be adjusted so that trough blood concentrations are within 3-8 ng/mL. In detail: Tacrolimus (Prograf or FDA approved generic 0.5 mg, 1 mg or 5 mg capsules, twice a day) in combination with Everolimus (Zortress, 0.25, 0.5 and 0.75 tablets).
Study NCT02062892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Patients will be stable kidney transplant patients who are receiving an immunosuppressive drug regimen based on tacrolimus and sirolimus. 24 hours after the last sirolimus dose, the patients randomized to the tacrolimus/sirolimus arm of the study will remain on tacrolimus/sirolimus. In detail: Tacrolimus (Prograf or FDA approved generic 0.5 mg, 1 mg or 5 mg capsules, once a day) in combination with Sirolimus (Rapamune, 0.5, 1, and 2mg tablets).
Study NCT02056665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MINOCYCLINE
Description: Pill Minocycline 50 mg capsule
Study NCT02056665 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MINOCYCLINE
Description: Pill Minocycline 50 mg capsule
Study NCT02056665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLACEBO (for Minocycline)
Description: Pill manufactured to mimic Minocycline 50 mg capsule
Study NCT02056665 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO (for Minocycline)
Description: Pill manufactured to mimic Minocycline 50 mg capsule
Study NCT00969761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI-6727
Description: Low to high dose (administered every 3 weeks). Depending on the toxicities observed, intermediary dose levels may be added
Study NCT01443650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alirocumab SAR236553 (REGN727)
Description: Pharmaceutical form:solution Route of administration: subcutaneous
Study NCT00969761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 6727
Description: low to high dose
Study NCT02181361 — intervention group
Intervention type: DRUG
Intervention: hirudin plus aspirin
Description: natural hirudin 0.75g, three times a day (Brand name: Maixuekang capsule, Guizhou Xinbang Pharmaceutical Co., China) and aspirin 100mg, once daily
Study NCT02181361 — intervention group
Intervention type: DRUG
Intervention: Warfarin
Description: an initial dose of 1.25mg once daily. Three days later, INR of patients was checked every three days and the dose of warfarin was adjusted until reach the target range of 2 to 3. Since then INR monitoring was performed at 1, 2, 3, 6, 9, 12 months after stroke onset, targeting an INR between 2 and 3 and the dose of warfarin was adjusted accordingly.
Study NCT01643850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCS110
Description: Patients will receive up to 6 doses of MCS110 (3 or 5 or 10mg/kg) administered intravenously once every 4 weeks. Before each dosing, safety will be assessed.
Study NCT01643850 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a single dose of NaCl on day 1 through intravenous infusion.
Study NCT00992381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PN400
Description: 500mg Naproxen and 20mg esomeprazole
Study NCT00992381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naprosyn
Description: 500mg Naproxen
Study NCT03376776 — intervention group
Intervention type: PROCEDURE
Intervention: Vitrectomy
Study NCT01071941 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: administration of rRp450 into the hepatic artery
Description: Administration of rRp450 into the hepatic artery either as a single infusion, or as four infusions administered every one to two weeks.
Study NCT01571284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFLIBERCEPT AVE0005
Description: Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous
Study NCT01571284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: irinotecan, 5-FU and leucovorin
Study NCT01010568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab and Bendamustine
Description: Ofatumumab 300-mg IV on Day 1 of week -1 and then 1000 mg on Day 1 of each cycle for 6 cycles Bendamustine 70 mg/m2 IV on days 1 and 2 of each cycle for 6 cycles
Study NCT01719029 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate/Higher Fat Diet
Study NCT01719029 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Carbohydrate/Low fat diet
Study NCT03510468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide
Description: Each tablet contains 25 mg of tenofovir alafenamide.
Study NCT03510468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifapentine
Description: Each tablet contains 150 mg of rifapentine. Participants who weigh 45 to \< 50 kg will take 750 mg (5 tablets), and participants who weigh (Bullet) 50 kg will take 900 mg (6 tablets).
Study NCT03510468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH)
Description: Each tablet is formulated as 100 or 300 mg of isoniazid.
Study NCT03510468 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pyridoxine
Description: Each tablet contains 50 mg of pyridoxine
Study NCT04911400 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper-lower clear plastic retainers + Class III elastics
Description: Addition of Class III elastics to clear plastic retainers
Study NCT04911400 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Upper-lower clear plastic retainers
Description: Upper-lower clear plastic retainers
Study NCT04533360 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: VITROS Anti-SARS-CoV-2 IgG test
Description: The VITROS Anti-SARS-CoV-2 IgG test is a lateral flow immunoassay produced by Ortho-Clinical Diagnostics Inc.
Study NCT02622802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: In an ex vivo placenta perfusion study, placental tissue is exposed to paracetamol
Study NCT02622802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythromycin
Description: In an ex vivo placenta perfusion study, placental tissue is exposed to erythromycin
Study NCT02622802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: In an ex vivo placenta perfusion study, placental tissue is exposed to azithromycin
Study NCT03995680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mebendazole
Description: Treatment with one of the two formulations of mebendazole. The only difference between both arms is the type of formulation of the drug: chewable versus swallowable tablet.
Study NCT00613249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapivirine Gel 4750, 0.05%, 2.5g
Description: intravaginal gel, dosed daily
Study NCT00613249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapivirine Gel 4789, 0.05%, 2.5g
Description: intravaginal gel, dosed daily
Study NCT00613249 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HEC-based Placebo Gel
Description: intravaginal gel, dosed daily
Study NCT03386682 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ESTYME® MATRIX Breast Implants
Description: Breast implant surgery in breast reconstruction or breast augmentation
Study NCT03696511 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthodontic miniscrew insertion
Description: orthodontic treatment using miniscrews as anchorage reinforcement
Study NCT03995680 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mebendazole
Description: Treatment with one of the two formulations of mebendazole. The only difference between both arms is the type of formulation of the drug: chewable versus swallowable tablet.
Study NCT04213781 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HappyMed Video Glasses
Description: HappyMed allows the immersion of patients in films, cartoons or concerts.
Study NCT04213781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: The dosage is modified according to the Dixon's up-and-down method (using 0.5 µg/ml as a step size). The first patient in each group will start at a dose 3 µg/ml propofol. If patient manifests discomfort then the next patient will receive an increment of 0.5 µg/ml propofol, if patient is comfortable, then the next patient received a decrement of 0.5 µg/ml propofol.
Study NCT04213781 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Propofol
Description: The dosage is modified according to the Dixon's up-and-down method (using 0.5 µg/ml as a step size). The first patient in each group will start at a dose 3 µg/ml propofol. If patient manifests discomfort then the next patient will receive an increment of 0.5 µg/ml propofol, if patient is comfortable, then the next patient received a decrement of 0.5 µg/ml propofol.
Study NCT04213781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: 0.1 µg/kg
Study NCT04213781 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sufentanil
Description: 0.1 µg/kg
Study NCT02370004 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resistive Flexibility and Strength Training
Description: RFST is a physical therapy technique where a certified practitioner extends or flexes a joint with the subject actively resists the motion applied by the practitioner.~During the RFST treatment a subject will lie on a massage table while the practitioner holds the subject's arm or leg and flexes or extends the limb, instructing the patient to resist the flexion or extension produced by the practitioner. The process is repeated a number of times for each muscle while varying joint positions.
Study NCT00916058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: 30 mg/m\^2 given on day 2 of melphalan
Study NCT00916058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 100 mg/m\^2 for 2 days (70 mg/m\^2 for patients with Creatinine Clearance \<70 ml/min)
Study NCT00916058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: 60 mg/m\^2 given on the 2nd day of melphalan
Study NCT00916058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: 90 mg/m\^2 given on the 2nd day of melphalan
Study NCT00916058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: 60 mg/m\^2 given on the 1st and 2nd day of melphalan
Study NCT00916058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: 90 mg/m\^2 given on the 1st day of melphalan and 60 mg/m\^2 given on the 2nd day of melphalan
Study NCT00916058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: 125 mg/m\^2 given on the 1st day of melphalan and 100mg/m\^2 given on the 2nd day of melphalan
Study NCT00278902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-334543, EGFR/ErbB2 inhibitor; oral
Description: Part 1: single dose and multiple dose, escalating; Part 2: multiple dose, single schedule
Study NCT03798054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine/Lixisenatide (HOE901/AVE0010)
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study NCT03798054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine (HOE901)
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study NCT03798054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lixisenatide (AVE0010)
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study NCT03798054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT03798054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT03798054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SGLT2 inhibitor
Description: Pharmaceutical form:tablet~Route of administration: oral
Study NCT03798054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor
Description: Pharmaceutical form:tablet~Route of administration: oral
Study NCT03385265 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DIPPer Academy
Description: The DIPPer Academy curricula will build on treatment models guided by the Health Beliefs Model (HBM) and Social Cognitive Theory (SCT). The curricula includes video microlectures, personalize progress reports, and other features delivered via the internet.
Study NCT01251081 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: extra high volume hemofiltration
Description: extra high volume hemofiltration (85 mL/kg/h, EHVHF)
Study NCT01251081 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: high volume hemofiltration
Description: high volume hemofiltration (50 mL/kg/h, HVHF)
Study NCT03385265 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Parents in the standard of care control group will be instructed to manage their child's T1D as recommended by the diabetes team.
Study NCT01539343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antimicrobial Solution
Description: Antimicrobial solution, consisting of minocycline in combination with 30mg/ml of a chelator (EDTA) in 25% ethanol solution (HEAL solution), instilled in central venous catheter (CVC) catheter for 2 hours once daily for a minimum of 5 consecutive days. Lock therapy also received once weekly for two additional weeks.
Study NCT03604874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: intravenous infusion
Study NCT03604874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: intravenous infusion
Study NCT01779700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fingolimod
Description: 0.5mg each day of 8 week cycle
Study NCT05726565 — intervention group
Intervention type: OTHER
Intervention: multidisciplinary cardiac rehabilitation
Description: A heart failure disease management program was delivered to all patients before discharge, including an HF specialist nurse education program, dietitian consultation, physiatrist consultation, and psychologist consultation and assessment. Participants were advised to receive phase II CR after the CPET within one month. Moderate continuous aerobic exercise training was prescribed individually according to the CPET result.4 The training intensity was within 10 beats of the anaerobic threshold or 40-60% of peak VO2. The training intensity was gradually increased fortnightly as tolerated (Borg's scale of 12-14). Phase II CR consisted of 12 weeks of 36 sessions in the entire course. Patients who received at least one exercise session were considered as receiving CR. Other patients were considered non-receiving CR.
Study NCT06413420 — intervention group
Intervention type: DRUG
Intervention: Sunosi (solriamfetol)
Description: Exposure to at least 1 dose of solriamfetol at any time during pregnancy.
Study NCT06413420 — intervention group
Intervention type: DRUG
Intervention: Other prescription wake-promoting medications or stimulants
Description: Exposure to at least 1 dose of a prescription wake-promoting medication or stimulant at any time during pregnancy.
Study NCT06413420 — intervention group
Intervention type: OTHER
Intervention: No treatment
Description: No treatment
Study NCT04174989 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plasma treated with ClearPlasma (Extra-corporeal plasma filtration device)
Description: ClearPlasma is designed to specifically extract plasminogen, a protein that drives fibrinolysis, from up to 250 mL of plasma. ClearPlasma is a non-pyrogenic, sterile, single-use medical device that is indicated for use in conditions where massive bleeding situations exist.
Study NCT04174989 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Regular fresh-frozen plasma (not treated)
Description: Regular fresh-frozen plasma (not treated)
Study NCT03964246 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassion Meditation (CM) intervention
Description: 10 weekly 90-minute sessions. Sessions 1-3 assist participants in basic mindfulness breathing practices; sessions 4-8 focus on personal analysis of factors underlying difficulties with compassion for self or others; sessions 9 and 10 review content and assist with relapse prevention.~\[These were planned as in-person groups but due to the COVID-19 social distancing requirements that started after initiation of cohort 1, the investigators had to retool the intervention for telehealth delivery.\]
Study NCT03964246 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Aging Psychoeducation
Description: The investigators planned to administer a 10-week psychoeducational in-person group focused on topics in healthy aging to examine its feasibility as a control condition for a subsequent randomized controlled trial. This would include use of an existing library of videotaped community-focused talks, such as increasing happiness, mental resilience and health, nutrition, and physical activity.~\[Unfortunately, with the switch to telehealth format necessitated by the COVID-19 social distancing requirements, the consensus of the investigators and staff was that these proved too be too dry/dull/academic to be a credible attention control in a telehealth format for the target population.\]
Study NCT03855631 — intervention group
Intervention type: GENETIC
Intervention: Intervention on primary cultured cells
Description: The intervention includes primary cultured cells, reprograming them into mesenchymal stem cells and CRISPR/Case9 gene therapy treatment on patients' cells
Study NCT04582435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Icodec
Description: Participants will receive 1 dose from a prefilled pen, administered subcutaneously (under the skin), once a week by designated study staff, for a total of at least 8 and a maximum of 16 doses which equals 8-16 weeks of treatment.
Study NCT02667223 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cohort 1: bococizumab 150 mg + rHuPH20
Description: bococizumab 150 mg + rHuPH20 administered SC to healthy volunteers
Study NCT02667223 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cohort 2: bococizumab 300 mg
Description: bococizumab 300 mg administered SC to healthy volunteers
Study NCT01779700 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 tablet each day of 8 week cycle
Study NCT02667223 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cohort 3: bococizumab 300 mg + rHuPH20
Description: bococizumab 300 mg + rHuPH20 administered SC to healthy volunteers
Study NCT02667223 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cohort 5: bococizumab 450 mg + rHuPH20
Description: bococizumab 450 mg + rHuPH20 administered SC to healthy volunteers
Study NCT02667223 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cohort 4: bococizumab 300 mg + rHuPH20
Description: bococizumab 300 mg + rHuPH20 administered SC to subjects with hypercholesterolemia receiving a statin
Study NCT03042377 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single-Visit Retreatment
Description: The teeth in this group were treated according to the guidelines for root canal retreatment in single-session. The filling was removed and cavity was opened. Then root canal filling was removed from the root canals completely using retreatment kit. After irrigation protocol, root canals were obturated with gutta percha and coronal restoration was made using composite and/or fully crown if necessary.
Study NCT03042377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multiple-Visit-Calcium Hydroxide
Description: The teeth in this group were treated according to the guidelines for root canal retreatment in multiple-session. The filling was removed and cavity was opened. Then root canal filling was removed from the root canals completely using retreatment kit. After irrigation protocol, root canals were treated with calcium hydroxide and the cavity was filled with temporary restorative material.
Study NCT03042377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multiple-Visit-Corticosteroid Paste
Description: The teeth in this group were treated according to the guidelines for root canal retreatment in multiple-session. The filling was removed and cavity was opened. Then root canal filling was removed from the root canals completely using retreatment kit. After irrigation protocol, root canals were treated with corticosteroid \& antibiotic paste and the cavity was filled with temporary restorative material.
Study NCT03042377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multiple-Visit-Antibiotic Paste
Description: The teeth in this group were treated according to the guidelines for root canal retreatment in multiple-session. The filling was removed and cavity was opened. Then root canal filling was removed from the root canals completely using retreatment kit. After irrigation protocol, root canals were treated with an antibiotic paste and the cavity was filled with temporary restorative material.
Study NCT01702376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retosiban 100 mg
Description: Subjects will be administered with single dose of one moxifloxacin placebo tablet, one 100 mg tablet of retosiban and 7 retosiban matched placebo tablets